There has got to be a consideration about the buy-out premium on botanix x sofdra - people in the forum are talking about 18-24 months for us to really see what we actually have with sofdra, medtech/pharma co are decades past doing their own R&D and are happy to pay a short-term premium on pre-rev/very-early rev (bot) companies. The question is; who will buy it? I agree with others regarding a 'buy' sentiment; $70M in the kitty will let the team do their thing and allow them adequate runway to shop around for buyout partners. Without the CR, it'd be a different story.
There has got to be a consideration about the buy-out premium on...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.015(4.11%) |
Mkt cap ! $689.3M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 38.5¢ | 35.8¢ | $2.121M | 5.700M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 22200 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 246082 | 7 |
View Market Depth
| Last trade - 16.10pm 26/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |